ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Growth Hormone
Phase 2

Ipamorelin

Ipamorelin

Also known as: IPA, NNC 26-0161

Overview

Key Facts

Primary Goal: A highly selective growth hormone releasing peptide (GHRP) that stimulates GH release through the ghrelin receptor without significantly affecting cortisol, prolactin, or appetite

A highly selective growth hormone releasing peptide (GHRP) that stimulates GH release through the ghrelin receptor without significantly affecting cortisol, prolactin, or appetite. Considered one of the cleanest GH secretagogues available. Half-Life ~2 hours Typical Dose 100–300 mcg Frequency 2-3 times daily Cycle Length 8-16 weeks

Dosing Information

Half-Life

~2 hours

Typical Dose

100–300 mcg

Frequency

2-3 times daily

Cycle Length

8-16 weeks

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Phase 2

Ipamorelin has been studied in multiple clinical trials including mail-operative ileus and growth hormone deficiency models. Research consistently demonstrates dose-dependent GH release with a favorable selectivity profile, showing no clinically significant increases in ACTH, cortisol, or prolactin at therapeutic doses. It is widely regarded as the most side-effect-friendly GHRP.

Frequently Asked Questions

Common questions about Ipamorelin

UK-Specific Information

Exclusive data points and guidance for UK residents using Ipamorelin

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With